A Randomized, 5-Part, Intravenous Study of the Safety, Tolerability, Bioequivalence, and Drug Interaction Potential of Final Market Image Formulation of MK0517 in Young Healthy Subjects.

Trial Profile

A Randomized, 5-Part, Intravenous Study of the Safety, Tolerability, Bioequivalence, and Drug Interaction Potential of Final Market Image Formulation of MK0517 in Young Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Fosaprepitant (Primary) ; Aprepitant; Midazolam
  • Indications Chemotherapy-induced nausea and vomiting; Nausea and vomiting; Postoperative nausea and vomiting
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 Oct 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top